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Nonsyndromic X-linked mental retardation (NSXLMR) is a very heterogeneous condition, and most of the un-
derlying gene defects are still unknown. Recently, we have shown that ∼30% of these genes cluster on the proximal
Xp, which prompted us to perform systematic mutation screening in brain-expressed genes from this region. Here,
we report on a novel NSXLMR gene, FTSJ1, which harbors mutations in three unrelated families—one with a
splicing defect, one with a nonsense mutation, and one with a deletion of one nucleotide. In two families, subsequent
expression studies showed complete absence or signiﬁcant reduction of mutant FTSJ1 transcripts. FTSJ1 protein
is a homolog of Escherichia coli RNA methyltransferase FtsJ/RrmJ and may play a role in the regulation of
translation. Further studies aim to elucidate the function of human FTSJ1 and its role during brain development.
X-linked mental retardation (XLMR) is a genetically and
clinically heterogeneous group of disorders of the brain
affecting 1/600 males (Herbst and Miller 1980). Non-
syndromic XLMR (NSXLMR) accounts for approxi-
mately two-thirds of all cases, and as many as 100 dif-
ferent genes on the X chromosome may be involved in
this condition (Gecz andMulley 2000). Most of the genes
underlying NSXLMR remain unknown. As can be con-
cluded from the distribution of linkage intervals in 125
families with NSXLMR, ∼30% of all relevant mutations
cluster on the proximal short arm of the X chromosome
(Ropers et al. 2003). PQBP1 (MIM 300463), which en-
codes the polyglutamine binding protein 1, and ZNF41
(MIM 314995) were the ﬁrst two XLMR genes that we
identiﬁed in this region (Kalscheuer et al. 2003; Shoichet
et al. 2003).
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Here, we report on the identiﬁcation of a novel
NSXLMR gene in this region. FTSJ1 is a human homolog
of the Escherichia coli 2′-O-rRNAmethyltransferase FtsJ/
RrmJ gene (Ogura et al. 1991; Caldas et al. 2000) and
is functionally unrelated to all previously identiﬁed
NSXLMR genes.
The patient panel for mutation screening included 29
families with XLMR with overlapping linkage intervals
and 215 small families with XLMR collected by the
European MRX Consortium. All samples were obtained
after receiving informed consent.
Family MRX44 has been published previously; all af-
fected males have mild to moderate mental retardation
(Hamel et al. 1999).
In family P48, the mother of the index patient is a
healthy carrier with normal intelligence and adaptive
skills. The index patient was born after normal pregnancy
without fetal distress. Chromosome analysis indicated a
normal karyotype, and fragile X (FRAXA) screening was
negative. The patient ﬁrst walked at age 18 mo and spoke
at age 3–4 years. At the age of 29 years, he is now able
to read simple sentences but has difﬁculties extracting the
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Figure 1 A, Pedigree for family MRX44 with a splice-site mu-
tation in exon 9, shown together with sequence chromatograms from
a control and from one affected individual from this family, marked
with an asterisk (*) in the pedigree. The affected nucleotide, which
results in skipping of exon 9 in male patients, is indicated by a black
arrow. Exonic nucleotides are shown in uppercase letters, and intronic
nucleotides are shown in lowercase letters. B, Pedigree for family P48
with a nonsense mutation in exon 4 is shown together with the control
and patient sequence chromatograms. A black arrow indicates the
affected nucleotide. C, Pedigree for family A3 with a single-base-pair
deletion affecting splicing of exon 2, together with sequence chro-
matograms from a control and the patient, who is marked with an
asterisk in the pedigree. Affected nucleotides are circled.
meaning. Behavior problems, including aggressive out-
bursts, were treated with antipsychotic pharmaceuticals,
including carbamazepine. On recent clinical examination,
his height was 170 cm, his weight was 80 kg (mild
obesity), and his head circumference was 61 cm (3 SD).
He had a ﬂat midface but otherwise normal features, and
neurological examinations, including brain magnetic res-
onance imaging and electroencephalogram, indicated no
abnormalities. Clinical records of his affected uncle are
not available, but pregnancy and delivery were normal,
and the mental retardation was said to be mild to
moderate.
Family A3 has six affected males, all of whom exhibit
mild to moderate intellectual disabilities. Individuals II:
3, II:12, III:1, and III:5 have all attended special schools,
sheltered workshops, or work education courses. Al-
though they are all able to function essentially indepen-
dently in familiar environments, they all require assis-
tance with ﬁnances. In addition, patients II:3, III:1, and
III:5 have problems with anger and aggression, and pa-
tients II:3 and III:1 are affected by anxiety and depres-
sion. Patients III:1 and III:5 have both been treated with
paroxetine to relieve these symptoms. Patient II:12 re-
cently received a diagnosis of schizophrenia and has been
treated with antipsychotic pharmaceuticals.
Patient III:4 exhibits a somewhat milder phenotype.
His disorder was ﬁrst recognized at the age of 2 years,
because of his delayed speech. However, he walked at
age 11 mo and never had behavior problems. He at-
tended a regular primary school, and, after participating
in a work education program, he obtained employment
in the catering industry, where he now undertakes clean-
ing, dishwashing, and simple food preparation tasks. He
is completely independent in managing his ﬁnances. On
recent examination, patient III:4 had a height of 170 cm
(15th percentile), a weight of 94.6 kg (95th percentile),
and a head circumference of 57.5 cm (75th percentile).
He has mild brachydactyly and a high palate.
Patient III:6 has the most signiﬁcant intellectual dis-
ability of any member of the family. His IQ has been
measured at !55, and he has attended special school
since the age of 7 years. Like his affected relatives, he
has problems with anger and aggression; for this, he is
being treated with amitriptyline. He walked at age 18
mo and ﬁrst spoke in sentences at ∼10 years of age. On
recent examination, he had no signiﬁcant dysmorphic
features. He is 167 cm tall (50th percentile), weighs 57
kg (75th percentile), and has a head circumference of
55 cm (50th percentile).
There are no signiﬁcant intellectual problems in the
obligate female carriers in family A3. For mutation de-
tection, PCR products corresponding to the complete
known human FTSJ1 coding sequence (GenBank acces-
sion number BC023584) were ampliﬁed from genomic
DNA using intronic primers (table A [online only]) (Gen-
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Figure 2 A, Sequence chromatograms from RT-PCR products,
indicating exon 9 splicing of FTSJ1 in an affected male from family
MRX44 and in a male control. Primers used for ampliﬁcations were
located in exon 7 and exon 10. Because of the mutation in exon 9,
the mutant FTSJ1 transcript lacks exon 9 completely. Vertical black
lines indicate the exon boundaries. B, Sequence chromatograms from
RT-PCR products, showing exon 2 and exon 3 splicing of FTSJ1 in a
male control (A) and in an affected male of family A3. Primers used
for ampliﬁcations were located in exon 2 and exon 5. Because of a 1-
bp deletion in the exon 2/intron 2 splice site of FTSJ1 in the patient,
an extra 10 nucleotides of intron 2 are present in the mutant FTSJ1
transcripts. Vertical black lines indicate the boundary between exon
2 and exon 3 in panel A and of intron 2 and exon 3 in panel B. Exonic
nucleotides are shown in uppercase letters, and intronic nucleotides
are in lowercase.
Figure 3 A,Northern blot analysis of poly-ARNA frompatient
and control lymphoblastoid cell lines. The blot was sequentially hy-
bridized with an FTSJ1 cDNA probe spanning exons 2–10 and a full-
length b-actin cDNA probe. B,Northern blot analysis of poly-ARNA
from a patient lymphoblastoid cell line (A3) and two control cell lines.
Hybridization was performed exactly as described in panel A.
Bank accession number AF196972), and pooled samples
were analyzed with the WAVE system (Transgenomic).
(Conditions are described in table B [online only]).
We found a single-nucleotide substitution (655GrA)
at the last nucleotide of exon 9 in family MRX44 (ﬁg
1A). Subsequent ampliﬁcation of patient cDNA resulted
in a fragment that was smaller than expected; direct
sequencing of this speciﬁc product revealed that exon 9
is absent in the patient (ﬁg. 2A). The absence of exon 9
introduces no frameshift in the FTSJ1 ORF, but the re-
sulting FTSJ1 protein lacks 28 amino acids, which alters
its structure and probably also its function. Subse-
quently, we searched for FTSJ1 mutations in 215 indi-
viduals from unrelated families with putative XLMR
(families for which no linkage data was available). This
analysis resulted in the detection of a single-nucleotide
substitution (196CrT) in exon 4 of family P48 (ﬁg. 1B).
The CrT exchange is a nonsense mutation that results
in a predicted truncated protein of 65 aa.
We also found a single-nucleotide deletion in fami-
ly A3 (ﬁg. 1C). This deletion affects one of the two
guanine nucleotides of the exon 2/intron 2 boundary
(IVS21delG). Direct sequencing of mutant RT-PCR
products from the patient showed that, at the boundary
between exon 2 and exon 3, the transcript carries an
insertion of a 10-bp sequence of intron 2 (ﬁg. 2B), which
indicates that the IVS21delG deletion affects splicing
by cryptic splice-site activation. The incorporation of the
intronic sequence leads to a frameshift in the FTSJ1
mRNA, which results in the use of a premature stop
codon in exon 3 at position 138, presumably producing
a truncated protein of 49 aa.
Sequencing of PCR-ampliﬁed FTSJ1 transcripts from
available family members showed that all affected males
carry the mutation and that all mutations cosegregated
with the disease (data not shown). None of these changes
was found in 200 control X chromosomes.
To gain more insight into the pathomechanism under-
lying NSXLMR in these three families, we performed
northern blot hybridizations of poly-A cell line RNA
from one affected male of each family, using a 744-bp
cDNA probe corresponding to FTSJ1 exons 2–10. In the
patient from family MRX44 with exon 9 skipping, FTSJ1
RNA level was identical to control RNA, indicating that
the mutated transcripts are stable (ﬁg. 3A). In contrast,
in mRNA from an affected male from family P48, who
carries the CrT substitution in exon 4, FTSJ1 transcripts
were almost undetectable (ﬁg. 3A). Likewise, in family
A3 with a premature stop codon in exon 3, FTSJ1 tran-
scripts were detected at a signiﬁcantly reduced level (ﬁg.
3B), suggesting that the phenotype in these families most
likely results from functional loss of FTSJ1 protein.
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Figure 4 Northern blot hybridization of multiple human tissues,
using a probe spanning exons 2–10 of human FTSJ1. A, Fetal tissues,
including brain, lung, liver, and kidney.B,Adult brain tissues, including
amygdala, caudate nucleus, corpus callosum, hippocampus, whole
brain, and thalamus. b-actin served as control for RNA loading.
When we performed northern blotting with an FTSJ1-
speciﬁc probe, a transcript of ∼2.4 kb was found in all
fetal and adult tissues examined, including brain, lung,
liver, and kidney. Remarkably, expression was highest
in fetal brain (ﬁg. 4A). In the adult brain, the highest
expression was observed in the caudate nucleus and the
lowest expression in the corpus callosum (ﬁg. 4B).
Extensive sequence comparisons of human FTSJ1
protein (GenBank accession numbers CAA06749 and
AAH23584) (also called “TRM7” and “JM23”; see
below) with homologous proteins in different species
showed that it belongs to a large phylogenetically con-
served family of RNA methyltransferases (Bugl et al.
2000; Feder et al. 2003). The counterpart of FTSJ1 in
E. coli is FtsJ/RrmJ, an RNA-binding heat shock protein
structurally related to S-adenosyl-L-methionine–depen-
dent methyltransferases. The substrate of FtsJ/RrmJ is
the 23S ribosomal RNA of ribosomal particles (Bugl et
al. 2000). Furthermore, three yeast proteins exhibit strik-
ing sequence similarities to E. coli FtsJ/RrmJ—namely,
Spb1 (suppressor of poly-A-binding protein Pab1p),
Mrm2 (mitochondrial rRNA methyltransferase 2), and
Trm7 (tRNA methyltransferase 7). These proteins are
present in different cell compartments—the nucleolus,
the mitochondria, and the cytoplasm, respectively—and
have different substrates. Spb1 protein is required for
25S rRNA synthesis (Pintard et al. 2000). Mrm2 is a
mitochondrial protein that is involved in 21S rRNA
methylation (Pintard et al. 2002a). Trm7 catalyzes the
formation of 2′-O-methylribose at two positions in the
anticodon loops of various tRNAs (Pintard et al. 2002b).
All yeast strains with a deletion of any one of these genes
show growth reduction due to reduced translation ef-
ﬁciency (Pintard et al. 2000, 2002a, 2002b). As in yeast,
the human genome contains three FtsJ/RrmJ homologs.
According to Feder et al. (2003), the human FTSJ1 pro-
tein is a member of the Trm7 subfamily, which suggests
that it may have a role in the posttranscriptional mod-
iﬁcation of tRNA. Experimental evidence on the func-
tion of human FTSJ1 is still lacking, but, on the basis
of sequence homology, there is good reason to believe
that this protein also plays a role in translation.
In affected males from family MRX44 (Hamel et al.
1999), the mutation leads to skipping of exon 9 and
results in a predicted protein that lacks the C-terminal
part of the S-AdoMet–binding domain. The deletion
probably affects the conserved protein structure, which
consists, in the homologous E. coli Ftsj/Rrmj protein, of
alternating a helices and b sheets (Bugl et al. 2000).
Despite the ubiquitous expression of FTSJ1, all mu-
tations identiﬁed in this study result in a relatively mild
phenotype that is essentially brain speciﬁc. It is possible
that the activity of FTSJ1 is most critical during brain
development, which is supported by relative high ex-
pression of FTSJ1 in fetal brain. It is also plausible that
brain structures are more sensitive to defects in the trans-
lation machinery than are other organs. Alternatively,
another protein may partially compensate for the loss
of FTSJ1, thereby preventing FTSJ1 mutations from
causing more severe disorders. In E. coli, overexpression
of two small GTPases was found to rescue a null mu-
tation in the FtsJ/RrmJ gene, which restored the impaired
ribosome assembly process and/or stability of 70S ri-
bosomes (Tan et al. 2002). Similarly, in yeast, functional
redundancy of the methyltransferase activity of Spb1
and a small nucleolar RNA-dependent mechanism has
been reported for the 2′-O-methylation of a conserved
nucleotide in the peptidyl-transferase center of the ri-
bosome (Bonnerot et al. 2003).
In summary, we have shown that mutations in the
methyltransferase FTSJ1 cause NSXLMR. Homolo-
gous methyltransferases modify untranslated RNAs
and thereby play critical roles in protein translation.
The association of FTSJ1 with mental retardation high-
lights the importance of this process, speciﬁcally in
brain development and cognitive processes. Current
studies aim to further characterize the function of
FTSJ1.
Acknowledgments
We sincerely thank the families for participation in this
study, G. Dellatolas for help with collecting samples, and S.
Shoichet for critical reading of the manuscript. This work was
supported by German Human Genome Program grant
01KW99087, National Genome Research Network grant
01GR0105, the Australian National Health and Medical Re-
search Council, and 5th European Union Framework grant
QLG3-CT-2002-01810.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Reports 309
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for FTSJ1
mRNA sequences [accession number BC023584], FTSJ1
protein [accession numbers CAA06749 and AAH23584],
and genomic BAC clone [accession number AF196972])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for PQBP1 and ZNF41)
References
Bonnerot C, Pintard L, Lutfalla G (2003) Functional redun-
dancy of Spb1p and a snR52-dependent mechanism for the
2′-O-ribose methylation of a conserved rRNA position in
yeast. Mol Cell 12:1309–1315
Bugl H, Fauman EB, Staker BL, Zheng F, Kushner SR, Saper
MA, Bardwell JC, Jakob U (2000) RNA methylation under
heat shock control. Mol Cell 6:349–360
Caldas T, Binet E, Bouloc P, Costa A, Desgres J, Richarme G
(2000) The FtsJ/RrmJ heat shock protein of Escherichia coli
is a 23 S ribosomal RNA methyltransferase. J Biol Chem
275:16414–16419
Feder M, Pas J, Wyrwicz LS, Bujnicki JM (2003) Molecular
phylogenetics of the RrmJ/ﬁbrillarin superfamily of ribose
2′-O-methyltransferases. Gene 302:129–138
Gecz J, Mulley J (2000) Genes for cognitive function: devel-
opment on the X. Genome Res 10:157–163
Hamel BC, Smits AP, van den Helm B, Smeets DF, Knoers NV,
van Roosmalen T, Thoonen GH, Assman-Hulsmans CF,
Ropers HH, Mariman EC, Kremer H (1999) Four families
(MRX43, MRX44, MRX45, MRX52) with nonspeciﬁc X-
linked mental retardation: clinical and psychometric data
and results of linkage analysis. Am J Med Genet 85:290–
304
Herbst DS, Miller JR (1980) Nonspeciﬁc X-linked mental re-
tardation II: the frequency in British Columbia. Am J Med
Genet 7:461–469
Kalscheuer VM, Freude K, Musante L, Jensen LR, Yntema
HG, Gecz J, Seﬁani A, et al (2003) Mutations in the poly-
glutamine binding protein 1 gene cause X-linked mental re-
tardation. Nat Genet 35:313–315
Ogura T, Tomoyasu T, Yuki T,Morimura S, Begg KJ, Donachie
WD, Mori H, Niki H, Hiraga S (1991) Structure and func-
tion of the ftsH gene in Escherichia coli. Res Microbiol 142:
279–282
Pintard L, Kressler D, Lapeyre B (2000) Spb1p is a yeast nu-
cleolar protein associated with Nop1p and Nop58p that is
able to bind S-adenosyl-L-methionine in vitro. Mol Cell Biol
20:1370–1381
Pintard L, Bujnicki JM, Lapeyre B, Bonnerot C (2002a)
MRM2 encodes a novel yeast mitochondrial 21S rRNA
methyltransferase. Embo J 21:1139–1147
Pintard L, Lecointe F, Bujnicki JM, Bonnerot C, Grosjean H,
Lapeyre B (2002b) Trm7p catalyses the formation of two
2′-O-methylriboses in yeast tRNA anticodon loop. Embo J
21:1811–1820
Ropers HH, HoeltzenbeinM, Kalscheuer V, YntemaH,Hamel
B, Fryns JP, Chelly J, Partington M, Gecz J, Moraine C
(2003) Nonsyndromic X-linked mental retardation: where
are the missing mutations? Trends Genet 19:316–320
Shoichet SA, Hoffmann K, Menzel C, Trautmann U, Moser
B, Hoeltzenbein M, Echenne B, Partington M, Van Bok-
hoven H, Moraine C, Fryns JP, Chelly J, Rott HD, Ropers
HH, Kalscheuer VM (2003) Mutations in the ZNF41 gene
are associated with cognitive deﬁcits: identiﬁcation of a new
candidate for X-linked mental retardation. Am JHumGenet
73:1341–1354
Tan J, Jakob U, Bardwell JC (2002) Overexpression of two
different GTPases rescues a null mutation in a heat-induced
rRNA methyltransferase. J Bacteriol 184:2692–2698
